Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 5
2006 2
2007 6
2008 7
2009 12
2010 12
2011 11
2012 12
2013 11
2014 13
2015 14
2016 19
2017 8
2018 11
2019 16
2020 11
2021 8
2022 10
2023 11
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Tapia M, et al. Among authors: lluch a. Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. Cancers (Basel). 2023. PMID: 37760491 Free PMC article. Review.
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez JF, Candela-Noguera V, Lluch A, Bermejo B, Sancenón F, Cejalvo JM, Martínez-Máñez R, Eroles P. Garrido-Cano I, et al. Among authors: lluch a. ACS Appl Mater Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. Epub 2023 Aug 7. ACS Appl Mater Interfaces. 2023. PMID: 37549382 Free PMC article.
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
Fuentes-Antrás J, Martínez-Rodríguez A, Guevara-Hoyer K, López-Cade I, Lorca V, Pascual A, de Luna A, Ramírez-Ruda C, Swindell J, Flores P, Lluch A, Cescon DW, Pérez-Segura P, Ocaña A, Jones F, Moreno F, García-Barberán V, García-Sáenz JÁ. Fuentes-Antrás J, et al. Among authors: lluch a. Int J Mol Sci. 2023 Jul 13;24(14):11419. doi: 10.3390/ijms241411419. Int J Mol Sci. 2023. PMID: 37511178 Free PMC article.
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. Schettini F, et al. Among authors: lluch a. NPJ Breast Cancer. 2023 Apr 29;9(1):32. doi: 10.1038/s41523-023-00538-x. NPJ Breast Cancer. 2023. PMID: 37120452 Free PMC article. No abstract available.
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Among authors: lluch a. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.
Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells.
Oltra SS, Colomo S, Sin L, Pérez-López M, Lázaro S, Molina-Crespo A, Choi KH, Ros-Pardo D, Martínez L, Morales S, González-Paramos C, Orantes A, Soriano M, Hernández A, Lluch A, Rojo F, Albanell J, Gómez-Puertas P, Ko JK, Sarrió D, Moreno-Bueno G. Oltra SS, et al. Among authors: lluch a. Cell Death Differ. 2023 May;30(5):1366-1381. doi: 10.1038/s41418-023-01143-y. Epub 2023 Mar 11. Cell Death Differ. 2023. PMID: 36899106 Free PMC article.
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
Torres-Ruiz S, Tormo E, Garrido-Cano I, Lameirinhas A, Rojo F, Madoz-Gúrpide J, Burgués O, Hernando C, Bermejo B, Martínez MT, Lluch A, Cejalvo JM, Eroles P. Torres-Ruiz S, et al. Among authors: lluch a. Int J Mol Sci. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. Int J Mol Sci. 2023. PMID: 36835014 Free PMC article.
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis.
Jiménez-Rodríguez B, Alba-Bernal A, López-López E, Quirós-Ortega ME, Carbajosa G, Garrido-Aranda A, Álvarez M, Godoy-Ortiz A, Queipo-Ortuño MI, Vicioso L, Díaz-Córdoba G, Roldán-Díaz MD, Velasco-Suelto J, Hernando C, Bermejo B, Julve-Parreño A, Lluch A, Pascual J, Comino-Méndez I, Alba E. Jiménez-Rodríguez B, et al. Among authors: lluch a. Int J Mol Sci. 2022 Dec 21;24(1):146. doi: 10.3390/ijms24010146. Int J Mol Sci. 2022. PMID: 36613590 Free PMC article.
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Vazquez JC, Antolin S, Ruiz-Borrego M, Servitja S, Alba E, Barnadas A, Lluch A, Martin M, Rodriguez-Lescure A, Sola I, Bonfill X, Urrutia G, Sanchez-Rovira P. Vazquez JC, et al. Among authors: lluch a. Clin Transl Oncol. 2023 Apr;25(4):941-958. doi: 10.1007/s12094-022-02998-2. Epub 2022 Nov 22. Clin Transl Oncol. 2023. PMID: 36417083 Review.
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano Á, García-Sáenz JÁ, Cejalvo JM, Herranz J, Torres R, Haba-Rodriguez J, Ayala F, Gómez H, Rojo F, Nielsen TO, Martin M. Asleh K, et al. Among authors: lluch a. Clin Cancer Res. 2023 Jan 17;29(2):389-400. doi: 10.1158/1078-0432.CCR-22-2191. Clin Cancer Res. 2023. PMID: 36346687 Free PMC article. Clinical Trial.
185 results